Hello!
To view this content, please sign up or log in – it’s free and easy! Stay ahead with curated regulatory insights designed for professionals like you.
Brief
On "06/03/2025", the "Medicines and Healthcare products Regulatory Agency (MHRA)" issued an update regarding "Lazertinib approved for use in combination with amivantamab for the treatment of adults with non-small cell lung cancer". The approval is based on a clinical trial where participants who received the combination treatment had a longer period without disease progression. Side effects may include skin problems, decreased appetite, nausea, and fever, but detailed information is available in the Patient Information Leaflet or SmPC on the MHRA website.
Highlights content goes here...
Hello!
To view this content, please sign up or log in – it’s free and easy! Stay ahead with curated regulatory insights designed for professionals like you.
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested